Hidehito HORINOUCHI· @HHorinouchi · X·· 1 天前评分70
正文 · 机器翻译
🆙#ESMO26 总统研讨会 II：#LCSM
🔥Krascendo 1：Divarasib (Diva) 与 Sotorasib (Soto) 或 Adagrasib (Ada) 在既往治疗过的局部晚期或转移性 KRAS G12C 突变 NSCLC 中的疗效与安全性
🎙️ @FSkoulidis
🔢LBA5
🎯显著改善的 PFS（9.8 对 5.7 月，HR 0.58；n=338）和 OS（17.7 对 12.0 月，HR 0.56，p=0.0005）
🎯ORR 58.4% 对 32.3%
🎯因 TRAEs 导致停药 4.8% 对 11.7%
☑️NCT06497556
🔗 https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/348
@OncoAlert @Larvol @myESMO @IASLC @KRASKickers
4 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
Krascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer
https://esmocongress.esmo.org🆙 #ESMO26 #LCSM Presidential Symposium 🔥Krascendo 1: Efficacy and Safety of Divarasib vs Sotorasib or Adagrasib in Previously Treated Locally Advanced or Metastatic KRAS G12C-Mutated NSCLC 🎙️ @FSkoulidis 🔢LBA5 🎯Met Primary and Key Secondary Endpoints: Divarasib Significantly Improved PFS and OS vs Sotorasib/Adagrasib ☑️NCT06497556 🔗 https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/348 @OncoAlert @Larvol @myESMO @IASLC @KRASKickers在 X 查看被引用的帖子
来源：Hidehito HORINOUCHI · x.com